Listed by the USPTO as ESPINOSA, CLAUDIA EDILMA
Tech Center 1600 • Art Units: 1624 1654
This examiner grants 51% of resolved cases
ESPINOSA, CLAUDIA EDILMA is assigned to tech center 1600 and art unit 1624. The profile covers 57 resolved cases, with an allowance rate of 50.9%. The median time to allowance is 1382 days. The limited record calls for caution in drawing broad conclusions, while the allowance rate is close to an even division and the median timeline is extended.
The interview lift is 56.1%, the strongest positive association in this profile. Mayo Foundation for Medical Education and Research, The Regents of the University of Michigan, and City University of Hong Kong are the listed top companies. The top firms are BALLARD SPAHR LLP, BOZICEVIC, FIELD & FRANCIS LLP, and BROWN RUDNICK LLP. Counsel may give interviews serious consideration when a direct discussion can resolve technical or claim-scope issues.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17413861 | LACHNOSPIRACEAE MITIGATES AGAINST RADIATION-INDUCED HEMATOPOIETIC/GASTROINTESTINAL INJURY AND DEATH, AND PROMOTES CANCER CONTROL BY RADIATION | Non-Final OA | The Regents of the University of Michigan |
| 17619025 | PREVOTELLA PREPARATIONS AND TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND OTHER LUNG CONDITIONS | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18162927 | METHODS FOR TREATING AMBLYOPIA | Final Rejection | City University of Hong Kong |
| 17625866 | CLOSTRIDIA CONSORTIA COMPOSITIONS AND METHODS OF TREATING OBESITY, METABOLIC SYNDROME AND IRRITABLE BOWEL DISEASE | Final Rejection | University of Utah Research Foundation |
| 18869591 | GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS | Final Rejection | ARIZONA BOARD OF REGENTS on behalf of the UNIVERSITY OF ARIZONA |
| 17598119 | CARBONIC ANHYDRASE VARIANTS FOR IMPROVED CO2 CAPTURE | Non-Final OA | SAIPEM S.P.A. |
| 17556857 | PURIFICATION OF FVIII FROM PLASMA USING SILICON OXIDE ADSORPTION | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18606023 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | Non-Final OA | Peptilogics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy50.9% of resolved applications examined by Claudia Edilma Espinosa were allowed (57 resolved cases), compared with 54.6% across Art Unit 1624 over the last five years.
This examiner's interview lift is +56.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Claudia Edilma Espinosa took 1,382 days on average from filing to allowance.
Claudia Edilma Espinosa examines applications in Art Unit 1624 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
